Endo puts Vasostrict case against U.S. FDA on hold

Endo International Plc on Monday said it would stay its lawsuit against the U.S. Food And Drug Administration until the end of the year after the FDA made new commitments on the regulation surrounding the active ingredient in its blood pressure medicine Vasostrict.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.